Holen Sie sich die Stockscreener-App
144.54
1.75%
-2.305
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt A?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$146.85
Offen:
$145.23
24-Stunden-Volumen:
263.94K
Relative Volume:
0.12
Marktkapitalisierung:
$40.74B
Einnahmen:
$7.23B
Nettoeinkommen (Verlust:
$1.41B
KGV:
29.03
EPS:
4.979
Netto-Cashflow:
$1.09B
1W Leistung:
-4.70%
1M Leistung:
-1.16%
6M Leistung:
+23.70%
1J Leistung:
+14.28%
1-Tages-Spanne:
$143.75
$146.46
1-Wochen-Bereich:
$143.75
$154.29
52-Wochen-Spanne:
$108.35
$163.75
Agilent Technologies Inc Stock (A) Company Profile
Firmenname
Agilent Technologies Inc
Sektor
Branche
Telefon
(408) 345-8886
Adresse
5301 STEVENS CREEK BLVD, SANTA CLARA, CA
Compare A vs TMO, DHR, NTRA, IQV, IDXX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
A
Agilent Technologies Inc
|
144.50 | 41.40B | 7.23B | 1.41B | 1.09B | 4.979 |
TMO
Thermo Fisher Scientific Inc
|
603.14 | 222.97B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.91 | 144.27B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
324.61 | 46.72B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
256.62 | 42.67B | 16.63B | 1.39B | 2.12B | 8.0674 |
IDXX
Idexx Laboratories Inc
|
518.37 | 40.98B | 4.45B | 1.10B | 1.06B | 13.59 |
Agilent Technologies Inc Stock (A) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Eingeleitet | HSBC Securities | Buy |
| 2026-01-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-12-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-08 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-10 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-17 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-05-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | Citigroup | Neutral |
| 2023-05-24 | Bestätigt | Credit Suisse | Outperform |
| 2023-05-24 | Bestätigt | Evercore ISI | Outperform |
| 2023-05-24 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-24 | Bestätigt | Robert W. Baird | Outperform |
| 2023-05-24 | Bestätigt | SVB Securities | Outperform |
| 2023-05-24 | Bestätigt | Stifel | Hold |
| 2023-05-24 | Bestätigt | TD Cowen | Outperform |
| 2023-05-24 | Bestätigt | Wells Fargo | Overweight |
| 2023-05-11 | Eingeleitet | Barclays | Equal Weight |
| 2023-01-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-07-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-02-23 | Bestätigt | BofA Securities | Buy |
| 2022-02-23 | Bestätigt | Citigroup | Buy |
| 2022-02-23 | Bestätigt | Cowen | Outperform |
| 2022-02-23 | Bestätigt | Evercore ISI | Outperform |
| 2022-02-23 | Bestätigt | Stifel | Hold |
| 2022-02-23 | Bestätigt | Wells Fargo | Overweight |
| 2021-11-23 | Bestätigt | BofA Securities | Buy |
| 2021-11-23 | Bestätigt | Cowen | Outperform |
| 2021-11-23 | Bestätigt | Stifel | Hold |
| 2021-03-18 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Hochstufung | UBS | Neutral → Buy |
| 2020-11-17 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Neutral |
| 2020-08-19 | Bestätigt | BofA Securities | Neutral |
| 2020-08-19 | Bestätigt | Citigroup | Neutral |
| 2020-08-19 | Bestätigt | Jefferies | Buy |
| 2020-08-19 | Bestätigt | Robert W. Baird | Outperform |
| 2020-08-19 | Bestätigt | SVB Leerink | Outperform |
| 2020-08-19 | Bestätigt | Stifel | Hold |
| 2020-08-19 | Bestätigt | Wells Fargo | Overweight |
| 2020-02-24 | Herabstufung | Needham | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-26 | Bestätigt | Needham | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | UBS | Buy → Neutral |
| 2019-07-16 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-15 | Herabstufung | Barclays | Overweight → Equal Weight |
Alle ansehen
Agilent Technologies Inc Aktie (A) Neueste Nachrichten
UBS Downgrades Agilent Technologies to Neutral From Buy, $165 Price Target - marketscreener.com
Agilent names Dow Wilson board chair after Koh Boon Hwee retires - Bitget
Agilent Names Dow Wilson Board Chair, Adds Former Stryker CFO Glenn Boehnlein - citybiz.co
Agilent Technologies Inc. Announces Board Changes, Effective September 4, 2026 - marketscreener.com
Agilent names new board chair, adds director By Investing.com - Investing.com Canada
Agilent names new board chair, adds director - Investing.com
Ex-Stryker finance chief joins Agilent (NYSE: A) board as chair role shifts - Stock Titan
Agilent Announces Retirement of Board Chair Koh Boon Hwee, Appointment of Glenn Boehnlein to Board of Directors - Business Wire
Agilent Technologies stock gains on digital pathology launch and raised 2026 outlook - AD HOC NEWS
Agilent (A) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance Singapore
Agilent Technologies, Inc. (A) Investor Outlook: Analyzing a 16.30% Potential Upside in the Diagnostics Sector - DirectorsTalk Interviews
Price to sales forward of Agilent Technologies, Inc. – MIL:1A - TradingView
Agilent Technologies stock gains as FDA-cleared S540MD slide scanner strengthens digital pathology p - AD HOC NEWS
Agilent Technologies | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Mikael Dolsten to sell Agilent (NYSE: A) stock - Stock Titan
Worker says Agilent fired him to mask race and age bias - hcamag.com
Agilent Technologies stock gains on digital pathology launch and strong Q3 figures - AD HOC NEWS
Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System - 01net
Agilent Technologies Launches FDA-Cleared S540MD Slide Scanner in US - marketscreener.com
Agilent launches FDA-cleared slide scanner in U.S. market - Investing.com
Agilent launches FDA-cleared slide scanner in U.S. market By Investing.com - Investing.com Australia
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Agilent launches new ICP-MS, GC Systems and Digital Lab Execution platform in India - indianpharmapost.com
Baird Adjusts Price Target on Agilent Technologies to $180 From $169, Keeps Outperform Rating - marketscreener.com
Agilent Unveils Next‑Gen Lab Technologies to Boost India’s Testing Efficiency and Compliance - Indianweb2.com
Agilent Technologies Inc (A) Looks 2.6% Overvalued on GF Value™ - GuruFocus
Agilent: The Recovery Is Real, But So Is The Valuation (NYSE:A) - Seeking Alpha
A SWOT Analysis: Agilent Technologies Inc (A) Reveals Financial Insights in 10-Q Filing - GuruFocus
Bond swap: Agilent (NYSE: A) offers to exchange $600M in 4.9% notes - Stock Titan
Agilent (NYSE: A) readies global debt program with $100M default triggers - Stock Titan
Agilent Technologies 3Q 2026: Revenue $1.88B, EPS $1.28— 10-Q Summary - TradingView
Agilent (NYSE: A) spends $950M on Biocare — see how Q3 earnings and debt shifted - Stock Titan
Tranche Update on Agilent Technologies, Inc. (NYSE:A)'s Equity Buyback Plan announced on May 29, 2024. - marketscreener.com
Agilent Technologies stock rises on Q3 beat and guidance - AD HOC NEWS
Agilent Introduces the Cary 635 FTIR Spectrometer - Business Wire
Agilent Technologies, Inc. Introduces The Cary 635 FTIR Spectrometer - marketscreener.com
Agilent launches Cary 635 FTIR spectrometer for laboratories - Investing.com
HSBC Adjusts Price Target on Agilent Technologies to $175 From $165, Maintains Buy Rating - marketscreener.com
AGILENT TECHNOLOGIES INC : HSBC RAISES TARGET PRICE TO $175 FROM $165 - Bitget
International Markets and Agilent (A): A Deep Dive for Investors - Yahoo Finance
Weekly Recap: Agilent (A) Q3 results and pharma reshoring opportunity - TradingView
Agilent Technologies, Inc. (A) Stock Analysis: Exploring a 13.36% Potential Upside in the Diagnostics & Research Sector - DirectorsTalk Interviews
Stronger Q3 Results and Raised Guidance Could Be A Game Changer For Agilent Technologies (A) - simplywall.st
Agilent Technologies Inc. stock underperforms Friday when compared to competitors - MarketWatch
Wells Fargo Adjusts Price Target on Agilent Technologies to $180 From $160, Keeps Overweight Rating - Moomoo
Agilent CEO on 3Q Earnings, Life Sciences Outlook - marketscreener.com
Agilent (NYSE) Expanded Non-GAAP Margin 320 bps. How Much Is Repeatable? - Yahoo Finance
Wells Fargo Initiates Agilent Technologies(A.US) With Buy Rating, Announces Target Price $180 - Moomoo
Agilent earnings analysis: questions answered and next catalysts - Investing.com
Rothschild & Co Redburn Adjusts Agilent Technologies Price Target to $180 From $160, Maintains Buy Rating - Moomoo
Agilent Technologies: Q3 Growth, Expanding Margins, And Raised Guidance - Seeking Alpha
Finanzdaten der Agilent Technologies Inc-Aktie (A)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):